Chitto Sarkar, DO
Neuromusculoskeletal Medicine & OMM · Port St Lucie, FLNPI 1477529360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by GSK at 25.9% of the total. Reporting peaked in 2019 at $542 and has fallen 93.4% since, to $36 in 2025.
Across 48 payments — averaging $49.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$617
- AstraZeneca$614
- Novo Nordisk$492
- Boston Scientific$146
- Lilly USA, LLC$125
- Johnson & Johnson$118
- plus $266 from 4 others
What the payments were for
- Food & beverage$2,31397%
- Education$653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $617 |
| AstraZeneca | 8 | $614 |
| Novo Nordisk | 22 | $492 |
| Boston Scientific | 1 | $146 |
| Lilly USA, LLC | 1 | $125 |
| Johnson & Johnson | 2 | $118 |
| Treace Medical Concepts, Inc. | 1 | $118 |
| Bayer | 1 | $115 |
| Corcept Therapeutics | 1 | $22 |
| Stimwave Technologies Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$249
- AREXVY$223
- WATCHMAN Access System$146
- MOUNJARO$125
- Ozempic$121
- BREZTRI$120
- Lapiplasty System$118
- BREZTRI AEROSPHERE$116
- Kerendia$115
- BEXSERO$112
- XARELTO$102
How this compares
$2,378 in reported general payments places this provider in the 85th percentile of 41 neuromusculoskeletal medicine & omm providers in Florida.
See all neuromusculoskeletal medicine & omm providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $34,835 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $30,186 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $21,506 |
| MounjaroTirzepatide | 19 | $20,983 |
| XareltoRivaroxaban | 11 | $18,237 |
| MyrbetriqMirabegron | 20 | $13,886 |
| SynthroidLevothyroxine Sodium | 31 | $3,221 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,681 |
| Rosuvastatin Calcium | 88 | $1,501 |
| Pioglitazone Hcl | 89 | $1,073 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,056 |
| Omeprazole | 45 | $961 |
| Atorvastatin Calcium | 108 | $874 |
| Gabapentin | 37 | $809 |
| Pravastatin Sodium | 40 | $669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $617 | $21,50621 claims |
| Lilly USA, LLCMounjaro | $125 | $20,98319 claims |
| Johnson & JohnsonXarelto | $118 | $18,23711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 neuromusculoskeletal medicine & omm providers in Florida.
Other neuromusculoskeletal medicine & omm in Port St Lucie
- Patricio EspinosaBoca Raton$245K
- Hassan BitarBrandon$12K
- Mohamad SalehTemple Terrace$11K
- Issachar DevineLake Mary$6K
- Ramon Lugo-SanchezMiramar$6K
- Glenn ChapmanBoynton Beach$2K
- Jesse KemmerlinSouth Miami$2K
- Jonathan QuinonezRiverview$1K
- Joel SteinFort Lauderdale$1K
- Xiawei ZhongOrlando$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.